Results 31 to 40 of about 53,176 (324)

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Deep-coverage whole genome sequences and blood lipids among 16,324 individuals. [PDF]

, 2018
Large-scale deep-coverage whole-genome sequencing (WGS) is now feasible and offers potential advantages for locus discovery. We perform WGS in 16,324 participants from four ancestries at mean depth >29X and analyze genotypes with four quantitative ...
Abecasis, Goncalo, Alver, Maris, Bloom, Jonathan M, Chaffin, Mark, Correa, Adolfo, Cupples, L Adrienne, Engreitz, Jesse M, Ernst, Jason, Esko, Tonu, Ganna, Andrea, Johnson, W Craig, Kathiresan, Sekar, Kellis, Manolis, Khera, Amit V, Lander, Eric S, Manichaikul, Ani, Mitchell, Braxton, Montasser, May, Natarajan, Pradeep, Neale, Benjamin M, NHLBI TOPMed Lipids Working Group, O'Connell, Jeffrey R, Peloso, Gina M, Perry, James A, Poterba, Timothy, Rich, Stephen S, Ripatti, Samuli, Rotter, Jerome I, Ruotsalainen, Sanni E, Salomaa, Veikko, Seed, Cotton, Surakka, Ida L, Vasan, Ramachandran S, Willer, Cristen J, Wilson, James G, Zekavat, Seyedeh Maryam, Zhou, Wei   +36 more
core   +2 more sources

Real‐World Effectiveness of PCSK9 Inhibitors in Reducing LDL‐C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Information on the real‐world use of proprotein convertase subtilisin kexin 9 inhibitors (PCKS9is) in familial hypercholesterolemia are limited.
Marcello Arca, Simone Celant, Pier Paolo Olimpieri, Antonietta Colatrella, Luca Tomassini, Laura D'Erasmo, Maurizio Averna, Alberto Zambon, Alberico Luigi Catapano, Pierluigi Russo   +9 more
doaj   +1 more source

Possibilities of lipid clinics in identifying patients with familial hypercholesterolemia

Российский кардиологический журнал, 2023
Aim. To assess the detection rate of familial hypercholesterolemia among outpa­tients visiting a lipidologist.Material and methods. We analyzed the causes and nature of lipid metabolism disorders in patients of the Adult Lipidology Center as follows ...
Z. F. Kim, A. S. Galyavich, D. I. Sadykova, L. M. Nurieva   +3 more
doaj   +1 more source

Ezetimibe therapy: mechanism of action and clinical update. [PDF]

, 2012
The lowering of low-density lipoprotein cholesterol (LDL-C) is the primary target of therapy in the primary and secondary prevention of cardiovascular events.
Dayspring, Thomas D, Phan, Binh An P, Toth, Peter P   +2 more
core   +1 more source

Diagnostic Characteristics of Familial Hypercholesterolemia in Children

Педиатрическая фармакология, 2020
Familial hypercholesterolemia is autosomal dominant hereditary disorder developing in in humans since birth and it is characterized by low-density lipoproteins concentration increase in blood.
Dinara I. Sadykova, Liliia F. Galimova, Eugenia S. Slastnikova   +2 more
doaj   +1 more source

Genomics knowledge and attitudes among European public health professionals. Results of a cross-sectional survey [PDF]

, 2020
Background The international public health (PH) community is debating the opportunity to incorporate genomic technologies into PH practice. A survey was conducted to assess attitudes of the European Public Health Association (EUPHA) members towards their
Baccolini, V., Barnhoorn, F., D'Andrea, E., de Vito, C., Marco, M. D., Marzuillo, C., Paget, D. Z., Pitini, E., Rosso, A., Unim, B., Villari, P.   +10 more
core   +2 more sources

Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK [PDF]

, 2017
Peer reviewedPublisher ...
Cather, Moyra, Haralambos, Kate, Humphries, Steve E, Kerr, Marion, Miedzybrodzka, Zofia, Pears, Robert, Watson, Melanie   +6 more
core   +2 more sources

The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies.

PLoS ONE, 2021
Hypercholesterolemia is a clinically relevant condition with an ascertained role in atherogenesis. In particular, its presence directly correlates to the risk of atherosclerotic cardiovascular disease (ASCVD).
Pietro Ferrara, Danilo Di Laura, Paolo A Cortesi, Lorenzo G Mantovani   +3 more
doaj   +1 more source

The 1(st) and the 2(nd) Italian Consensus Conferences on low-density lipoprotein-apheresis. A practical synopsis and update [PDF]

, 2016
The clinical indications and guidelines for low-density lipoprotein (LDL)-apheresis set by the 1(st) Italian Consensus Conference held in Ostuni in 1990 and completed in 1992, but never published, are reported schematically.
Stefanutti, Claudia
core   +1 more source